You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Three and 5-year data in patients receiving 48 Gy/4 Fr, 50 Gy/4 Fr, and 52 Gy/4 Fr

From: Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study

  48 Gy/4 Fr (n = 6) 50 Gy/4 Fr (n = 51) 52 Gy/4 Fr (n = 14)
OS (%) at 3/5 years 100/100 70/65 71/53
PFS (%) at 3/5 years 83/63 62/55 64/54
Cumulative incidence of LR (%) at 3/5 years 0/20 10/10 22/31
  1. OS Overall survival, PFS Progression free survival, LR Local recurrence